Harnessing the power of cytokines to restore immune function

OUR FOCUS

Brooklyn ImmunoTherapeutics is focused on exploring the role that the human immune system can have in treating patients with cancer and immunologic diseases, both as a single agent and in combination with other therapies.

Our most advanced program is studying the safety and efficacy of IRX-2, a human cell-derived (hd) IL-2 therapeutic in patients with head and neck cancer. In a Phase 2a clinical trial in head and neck cancer, IRX-2 was well-tolerated and demonstrated an overall survival benefit. Additional single agent and combination studies are either underway or planned in other solid tumor cancer indications.

LATEST NEWS

Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders

[ READ MORE ]

Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc.

[ READ MORE ]

Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.

[ READ MORE ]